Bavarian Nordic Posts Steady Q3 Revenue

The Danish vaccine maker reported third-quarter 2026 revenue of DKK 1,805 million and kept its full-year guidance unchanged.

Updated on Nov. 13, 2026 in Economic Indicators

Bavarian Nordic Posts Steady Q3 Revenue

Live Poll

Do you think access to routine vaccines is getting better or worse where you live?

Bavarian Nordic reported third-quarter 2026 revenue of DKK 1,805 million, roughly flat against DKK 1,795 million a year earlier. The company also maintained its full-year 2026 revenue guidance of approximately DKK 6,100 million.

Why it matters

Travel Health sales grew 22% in the quarter, driven by continued strong RabAvert/Rabipur demand and the ongoing launch of Vimkunya. Full-year EBITDA margin is expected to decline as revenue phasing and investment increase in the fourth quarter.

Bavarian Nordic's third-quarter revenue reached DKK 1,805 million, compared with DKK 1,795 million a year earlier, and nine-month revenue totaled DKK 4,897 million, up 2%. The fourth-quarter revenue phasing and the full breakdown of the expected full-year EBITDA margin decline were not detailed.

The players

Bavarian Nordic A/S

A Copenhagen-based biopharmaceutical company that develops and manufactures vaccines for travel health and public preparedness markets.

The details

Travel Health revenue rose 22% to DKK 1,144 million, led by RabAvert/Rabipur sales of DKK 886 million, up 37%, and Vimkunya sales of DKK 73 million, up 146%. Public Preparedness contributed DKK 606 million, and third-quarter EBITDA was DKK 621 million, a 34.4% margin.

Timeline

  1. August 2026: The European Commission approved use of the MVA-BN mpox and smallpox vaccine for children aged 2 to under 12.

  2. September 2026: Tarja Stenvall was appointed chief executive officer.

  3. October 8, 2026: The company issued upgraded full-year 2026 guidance, which was maintained in this report.

  4. October 15, 2026: Stenvall's CEO appointment took effect.

  5. April 2027: CFO Henrik Juuel is scheduled to step down.

Big Picture

The results reflect the post-2022 mpox outbreak, which spurred government stockpiling of smallpox and mpox vaccines and shaped Public Preparedness demand. The company's Travel Health growth similarly depends on sustained demand for rabies and travel vaccines.

Travel Health revenue growth may bring continued availability of rabies and travel vaccines for those planning trips abroad. The company's guidance is unchanged, so no immediate change in product pricing or supply was reported.

The takeaway

Steady travel-vaccine demand and public-preparedness contracts can offset slower segments, so investors watching this company should track whether its margin guidance holds in the fourth quarter.

What happens next

Bavarian Nordic's CFO Henrik Juuel is scheduled to step down in April 2027, and the Board has initiated the search for his successor.

Further reading

For broader context on company earnings and market signals, explore Economic Indicators.

Live Poll

Do you think access to routine vaccines is getting better or worse where you live?